The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Treatment of HER2-positive breast cancer: current status and future perspectives
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab is also approved and widely used for patients with metastatic HER2-positive disease in combination with paclitaxe”
BackgroundUntangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 1×
“It belongs to a family of four receptors (EGFR/HER1, HER2, HER3, HER4) that are involved in regulating cell growth, survival and differentiation through interlinked signal transduction involving activation of the PI3K/Akt and the Ras/Raf/MEK/MAPK pathways ( Figure 1 )”
BackgroundSelf-citationTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Self-citationTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Self-citationGoldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Self-citationAdjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., Zambetti, M., Vazquez, F., Byakhow, M., Lichinitser, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61964-4 · Cited by 1,255
Self-citationThe PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227 · cited 1×
“177" language="eng" relation="no"> Introduction HER2 is a transmembrane receptor with tyrosine kinase activity but without a known ligand that was initially identified in a rat glioblastoma model”
BackgroundLamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,120
Self-citationJohnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“The genotype of the FcγRIIIa-158 correlates with response and progression-free survival (PFS) in patients receiving trastuzumab-based therapy for metastatic breast cancer, suggesting that ADCC is important in the antitumor activity of trastuzumab”
BackgroundMolina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 946
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., Ellis, C., Casey, M., Vukelja, S., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 942
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873 · cited 1×
“The monoclonal antibody, pertuzumab, binds to the HER2 ECD but at a different site to trastuzumab, and is able to inhibit ligand-induced dimerization of HER2 with its receptor partners”
BackgroundSelf-citationJunttila, T. T., Akita, R. W., Parsons, K., Fields, C., Lewis Phillips, G. D., Friedman, L. S., Sampath, D., & Sliwkowski, M. X. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.020 · Cited by 829
Self-citationCameron, D., Casey, M., Press, M., Lindquist, D., Pienkowski, T., Romieu, C. G., Chan, S., Jagiello-Gruszfeld, A., Kaufman, B., Crown, J., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9885-0 · Cited by 794
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 769
Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 764
Ewer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.300 · Cited by 726
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
Self-citationvon Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Self-citationBaselga, J., Semiglazov, V., van Dam, P., Manikhas, A., Bellet, M., Mayordomo, J., Campone, M., Kubista, E., Greil, R., Bianchi, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8391 · Cited by 636
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy
Lee-Hoeflich, S. T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0380 · Cited by 629
Self-citationHerceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., & Hasmann, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4597 · Cited by 622
Gianni, L., Dafni, U., Gelber, R. D., Azambuja, E., Muehlbauer, S., Goldhirsch, A., Untch, M., Smith, I., Baselga, J., Jackisch, C., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70033-x · Cited by 612
Self-citationKrop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
Self-citationSlamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Rolski, J., Chan, A., Mackey, J., Liu, M., Pinter, T., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-62 · Cited by 553
Junttila, T. T., Li, G., Parsons, K., Phillips, G. L., & Sliwkowski, M. X. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 541
Self-citationBurstein, H. J., Sun, Y., Dirix, L. Y., Jiang, Z., Paridaens, R., Tan, A. R., Awada, A., Ranade, A., Jiao, S., Schwartz, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8707 · Cited by 522
Spector, N. L., & Blackwell, K. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497
Burstein, H. J., Elias, A. D., Rugo, H. S., Cobleigh, M. A., Wolff, A. C., Eisenberg, P. D., Lehman, M., Adams, B. J., Bello, C. L., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5375 · Cited by 489
Robert, N., Leyland-Jones, B., Asmar, L., Belt, R., Ilegbodu, D., Loesch, D., Raju, R., Valentine, E., Sayre, R., Cobleigh, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1764 · Cited by 479
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5962 · Cited by 473
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Shi, F., Telesco, S. E., Liu, Y., Radhakrishnan, R., & Lemmon, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002753107 · Cited by 471
Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468
Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., Utriainen, T., Turpeenniemi-Hujanen, T., Jyrkkiö, S., Möykkynen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4577 · Cited by 458
HER2 therapy: Molecular mechanisms of trastuzumab resistance
Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433
Di Leo, A., Gomez, H. L., Aziz, Z., Zvirbule, Z., Bines, J., Arbushites, M. C., Guerrera, S. F., Koehler, M., Oliva, C., Stein, S. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2578 · Cited by 418
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Perez, E. A., Koehler, M., Byrne, J., Preston, A. J., Rappold, E., & Ewer, M. S. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60896-3 · Cited by 388
Self-citationXia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602468103 · Cited by 374
Spector, N. L., Xia, W., Burris, H., Hurwitz, H., Dees, E. C., Dowlati, A., O'Neil, B., Overmoyer, B., Marcom, P. K., Blackwell, K. L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.157 · Cited by 362
Chia, S., Norris, B., Speers, C., Cheang, M., Gilks, B., Gown, A. M., Huntsman, D., Olivotto, I. A., Nielsen, T. O., & Gelmon, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8659 · Cited by 301
Spielmann, M., Roché, H., Delozier, T., Canon, J.-L., Romieu, G., Bourgeois, H., Extra, J.-M., Serin, D., Kerbrat, P., Machiels, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0946 · Cited by 298
Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., Patnaik, A., Mathews, L., Ricart, A. D., Mays, T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0345 · Cited by 273
Raynaud, F. I., Eccles, S. A., Patel, S., Alix, S., Box, G., Chuckowree, I., Folkes, A., Gowan, S., De Haven Brandon, A., Di Stefano, F., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1200 · Cited by 271
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation
Schoeberl, B., Faber, A. C., Li, D., Liang, M.-C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., Nie, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3145 · Cited by 264
Gianni, L., Lladó, A., Bianchi, G., Cortes, J., Kellokumpu-Lehtinen, P.-L., Cameron, D. A., Miles, D., Salvagni, S., Wardley, A., Goeminne, J.-C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1661 · Cited by 262
Self-citationXia, W., Gerard, C. M., Liu, L., Baudson, N. M., Ory, T. L., & Spector, N. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208774 · Cited by 258
Mechanism of action of trastuzumab and scientific update
BASELGA, J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90276-3 · Cited by 258
Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., Pritchard, K., Eisen, A., Vandenberg, T., Taylor, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3033 · Cited by 258
Xia, W., Liu, L.-H., Ho, P., & Spector, N. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207166 · Cited by 253
Huang, X., Gao, L., Wang, S., McManaman, J. L., Thor, A. D., Yang, X., Esteva, F. J., & Liu, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3321 · Cited by 244
Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers
Mohsin, S. K., Weiss, H. L., Gutierrez, M. C., Chamness, G. C., Schiff, R., DiGiovanna, M. P., Wang, C.-X., Hilsenbeck, S. G., Osborne, C. K., Allred, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.661 · Cited by 244
Self-citationCurrent Status and Future Directions
Ito, F., & Chang, A. E. (2013) · Cited by 223
Rizzieri, D. A., Feldman, E., DiPersio, J. F., Gabrail, N., Stock, W., Strair, R., Rivera, V. M., Albitar, M., Bedrosian, C. L., & Giles, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1372 · Cited by 222
Junttila, T. T., Parsons, K., Olsson, C., Lu, Y., Xin, Y., Theriault, J., Crocker, L., Pabonan, O., Baginski, T., Meng, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3704 · Cited by 221
Self-citationPerez, E. A., Romond, E. H., Suman, V. J., Jeong, J., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kauffman, P. A., & Wolmark, N. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.512 · Cited by 218
Self-citationThe role of HER2 in angiogenesis
KUMAR, R. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90279-9 · Cited by 212
Kiewe, P., Hasmüller, S., Kahlert, S., Heinrigs, M., Rack, B., Marmé, A., Korfel, A., Jäger, M., Lindhofer, H., Sommer, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2436 · Cited by 197
Campbell, M. R., Amin, D., & Moasser, M. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1218 · Cited by 188
Schwartzberg, L. S., Franco, S. X., Florance, A., O'Rourke, L., Maltzman, J., & Johnston, S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0240 · Cited by 188
Arpino, G., Gutierrez, C., Weiss, H., Rimawi, M., Massarweh, S., Bharwani, L., De Placido, S., Osborne, C. K., & Schiff, R. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk151 · Cited by 188
Self-citationYin, W., Jiang, Y., Shen, Z., Shao, Z., & Lu, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021030 · Cited by 184
Peoples, G. E., Holmes, J. P., Hueman, M. T., Mittendorf, E. A., Amin, A., Khoo, S., Dehqanzada, Z. A., Gurney, J. M., Woll, M. M., Ryan, G. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1448 · Cited by 182
Lundgren, K., Zhang, H., Brekken, J., Huser, N., Powell, R. E., Timple, N., Busch, D. J., Neely, L., Sensintaffar, J. L., Yang, Y.-C., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0758 · Cited by 173
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
Dickler, M. N., Cobleigh, M., Miller, K. D., Klein, P. M., & Winer, E. P. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0055-9 · Cited by 167
Bria, E., Cuppone, F., Fornier, M., Nisticò, C., Carlini, P., Milella, M., Sperduti, I., Terzoli, E., Cognetti, F., & Giannarelli, D. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9663-z · Cited by 164
Blackwell, K. L., Pegram, M. D., Tan-Chiu, E., Schwartzberg, L. S., Arbushites, M. C., Maltzman, J. D., Forster, J. K., Rubin, S. D., Stein, S. H., & Burstein, H. J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn759 · Cited by 164
de Korte, M. A., de Vries, E. G. E., Lub-de Hooge, M. N., Jager, P. L., Gietema, J. A., van der Graaf, W. T. A., Sluiter, W. J., van Veldhuisen, D. J., Suter, T. M., Sleijfer, D. T., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.06.024 · Cited by 160
Xia, W., Husain, I., Liu, L.-H., Bacus, S. S., Saini, S., Spohn, J., Pry, K. J., Westlund, R. E., Stein, S. H., & Spector, N. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2101 · Cited by 148
Holmes, J. P., Benavides, L. C., Gates, J. D., Carmichael, M. G., Hueman, M. T., Mittendorf, E. A., Murray, J. L., Amin, A., Craig, D., Hofe, E. V., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7842 · Cited by 137
Yao, E. S., Zhou, W., Lee-Hoeflich, S. T., Truong, T., Haverty, P. M., Eastham‐Anderson, J., Lewin‐Koh, N., Gunter, B., Belvin, M. P., Murray, L. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2814 · Cited by 134
Self-citationGarnock-Jones, K. P., Keating, G. M., & Scott, L. J. (2010) · Drugs · doi:10.2165/11203700-000000000-00000 · Cited by 130
Wardley, A. M., Pivot, X. B., Morales-Vásquez, F., Zetina, L. M., Gauí, M. D. F. D., Reyes, D. O., Jassem, J., Barton, C. M., Button, P., Hersberger, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6531 · Cited by 127
Suzuki, E., Niwa, R., Saji, S., Muta, M., Hirose, M., Iida, S., Shiotsu, Y., Satoh, M., Shitara, K., Kondo, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1335 · Cited by 124
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
Lenihan, D. J., Suter, T. M., Brammer, M. G., Neate, C., Ross, G. A., & Baselga, J. M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr294 · Cited by 120
Baselga, J. M., Bradbury, I., Eidtmann, H., Cosimo, S. D., Aura, C. M., de Azambuja, E., Gómez, H., Dinh, P., Fauria, K., Dooren, V. V., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-s3-3 · Cited by 116
Köninki, K., Barok, M., Tanner, M., Staff, S. M., Pitkänen, J., Hemmilä, P., Ilvesaro, J. M., & Isola, J. J. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.002 · Cited by 113
Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies
Mori, K., Iida, S., Yamane‐Ohnuki, N., Kanda, Y., Kuni‐Kamochi, R., Nakano, R., Imai, H., Okazaki, A., Shinkawa, T., Natsume, A., et al. (2007) · Cytotechnology · doi:10.1007/s10616-007-9103-2 · Cited by 112
Horlock, C., Stott, B., Dyson, P. J., Morishita, M., Coombes, R. C., Savage, P. M., & Stebbing, J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604963 · Cited by 108
Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
de Azambuja, E., Bedard, P. L., Suter, T. M., & Piccart, M. J. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0112-2 · Cited by 108
Trastuzumab‐based neoadjuvant therapy in patients with HER2‐positive breast cancer
Chang, H. R. (2010) · Cancer · doi:10.1002/cncr.25120 · Cited by 107
Karagiannis, P., Singer, J., Hunt, J., Gan, S. K., Rudman, S. M., Mechtcheriakova, D., Knittelfelder, R., Daniels‐Wells, T. R., Hobson, P. S., Beavil, A. J., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0607-1 · Cited by 106
Carmichael, M. G., Benavides, L. C., Holmes, J. P., Gates, J. D., Mittendorf, E. A., Ponniah, S., & Peoples, G. E. (2009) · Cancer · doi:10.1002/cncr.24756 · Cited by 103
The E75 HER2/neu peptide vaccine
Mittendorf, E. A., Holmes, J. P., Ponniah, S., & Peoples, G. E. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0540-3 · Cited by 96
Hartford, C. M., Desai, A. A., Janisch, L. A., Karrison, T. G., Rivera, V. M., Berk, L., Loewy, J. W., Kindler, H. L., Stadler, W. M., Knowles, H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2076 · Cited by 96
Vázquez‐Martín, A., Colomer, R., Brunet, J., & Menéndez, J. A. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.4.769 · Cited by 96
Azémar, M., Djahansouzi, S., Jäger, E., Solbach, C., Schmidt, M., Maurer, A. B., Mross, K. B., Unger, C., von Minckwitz, G., Dall, P., et al. (2003) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000004371.48757.19 · Cited by 95
Jäger, M., Schoberth, A., Ruf, P., Hess, J., & Lindhofer, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2861 · Cited by 94
Dokmanovic, M., Hirsch, D. S., Shen, Y., & Wu, W. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0140 · Cited by 93
Ramanathan, R. K., Egorin, M. J., Erlichman, C., Remick, S. C., Ramalingam, S. S., Naret, C., Holleran, J. L., TenEyck, C. J., Ivy, S. P., & Belani, C. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0415 · Cited by 89
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90
Erlichman, C. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902953699 · Cited by 84
Arteaga, C. L., O’Neill, A., Moulder, S. L., Pins, M., Sparano, J. A., Sledge, G. W., & Davidson, N. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0482 · Cited by 82
Self-citationFinn, R. S., Bentley, G. V., Britten, C. D., Amado, R. G., & Busuttil, R. W. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01762.x · Cited by 76
Increasing the Affinity for Tumor Antigen Enhances Bispecific Antibody Cytotoxicity
McCall, A. M., Shahied, L., Amoroso, A. R., Horak, E. M., Simmons, H. H., Nielson, U., Adams, G. P., Schier, R., Marks, J. D., & Weiner, L. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.10.6112 · Cited by 72
Untch, M., Muscholl, M. W., Tjulandin, S., Jonat, W., Meerpohl, H. G., Lichinitser, M., Manikhas, A., Coumbos, A., Kreienberg, R., du Bois, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9709 · Cited by 72
Raja, S. M., Clubb, R. J., Bhattacharyya, M., Dimri, M., Cheng, H., Pan, W., Ortega-Cava, C. F., Reddi, A. L., Naramura, M., Band, V., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.10.6585 · Cited by 71
ASCO 2020 Gastrointestinal Cancers Symposium
Pinion, S. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30045-5 · Cited by 69
Gianni, L., Pieńkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch-Hernández, A., Семиглазов, В. Ф., Szado, T., & Ross, G. A. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-s3-2 · Cited by 67
Self-citationNahta, R., Shabaya, S., Ozbay, T., & Rowe, D. (2009) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/187569209790112337 · Cited by 66
Wagner, A. J., Hoff, D., LoRusso, P. M., Tibes, R., Mazina, K. E., Ware, J. A., Yan, Y., Derynck, M. K., & Demetri, G. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3501 · Cited by 66
Tolcher, A. W., Yap, T. A., Fearen, I., Taylor, A., Carpenter, C., Brunetto, A. T., Beeram, M., Papadopoulos, K. P., Yan, L., & Bono, J. S. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3503 · Cited by 64
Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer
Green, M. D., Francis, P. A., Gebski, V., Harvey, V., Karapetis, C. S., Chan, A., Snyder, R., Fong, A., Basser, R., & Forbes, J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp202 · Cited by 62
PI3K kinase and scaffold functions in heart
Damilano, F., Perino, A., & Hirsch, E. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05081.x · Cited by 59
Sessa, C., Tosi, D., Viganò, L., Albanell, J., Hess, D., Maur, M., Cresta, S., Locatelli, A., Angst, R., Rojo, F., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp504 · Cited by 59
Self-citationOcaña, A., & Amir, E. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.001 · Cited by 58
Bianchi, G., Albanell, J., EIERMANN, W., Vitali, G., Borquez, D., Viganò, L., Molina, R., Raab, G., Locatelli, A., Vanhauwere, B., et al. (2003) · PubMed · Cited by 58
Self-citationErtumaxomab: a trifunctional antibody for breast cancer treatment
Kiewe, P. M., & Thiel, E. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1553 · Cited by 56
Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent
Hanson, B., & Vesole, D. H. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903158934 · Cited by 56
Xia, W., Bacus, S. S., Husain, I., Liu, L.-H., Zhao, S., Liu, Z., Moseley, M. A., Thompson, J. W., Chen, F. L., Koch, K. M., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1041 · Cited by 55
Trastuzumab versus lapatinib: The cardiac side of the story
Azim, H. A., Azim, H. A., & Escudier, B. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.06.007 · Cited by 55
on behalf of the Navelbine® Herceptin® Project, Chan, A., Martín, M., Untch, M., Gil, M., Guillem-Porta, V., Wojtukiewicz, M. Z., Kellokumpu‐Lehtinen, P., Sommer, H. L., Georgoulias, V., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603351 · Cited by 53
Optimal dose and schedule of an HER‐2/neu (E75) peptide vaccine to prevent breast cancer recurrence
Holmes, J. P., Gates, J. D., Benavides, L. C., Hueman, M. T., Carmichael, M. G., Patil, R., Craig, D., Mittendorf, E. A., Stojadinovic, A., Ponniah, S., et al. (2008) · Cancer · doi:10.1002/cncr.23772 · Cited by 50
Mayer, E. L., Partridge, A. H., Harris, L. N., Gelman, R. S., Schumer, S., Burstein, H. J., & Winer, E. P. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0366-5 · Cited by 49
Krop, I. E., LoRusso, P. M., Miller, K. D., Modi, S., Yardley, D. A., Rodriguez, G., Agresta, S., Zheng, M., Amler, L. C., & Rugo, H. S. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-5090 · Cited by 46
Shapiro, G. I., Kwak, E. L., Baselga, J. M., Rodon, J. A., Scheffold, C., Laird, A., Bedell, C., & Edelman, G. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3500 · Cited by 45
Morse, M. A., Hobeika, A. C., Osada, T., Niedzwiecki, D., Marcom, P. K., Blackwell, K., Anders, C. K., Devi, G. R., Lyerly, H. K., & Clay, T. M. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-42 · Cited by 45
D’Alessio, A., Luca, A. D., Maiello, M. R., Lamura, L., Rachiglio, A. M., Napolitano, M., Gallo, M., & Normanno, N. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0649-x · Cited by 43
Jumping higher: is it still possible? The ALTTO trial challenge
Tomasello, G., de Azambuja, E., Dinh, P., Snoj, N., & Piccart, M. J. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.12.1883 · Cited by 42
Adjuvant targeted therapy in early breast cancer
Mackey, J. R., McLeod, D., Ragaz, J., Gelmon, K. A., Verma, S., Pritchard, K. I., Laing, K. E., Provencher, L., & Charbonneau, L. F. (2009) · Cancer · doi:10.1002/cncr.24114 · Cited by 39
PI3K Inhibition Overcomes Trastuzumab Resistance: Blockade of ErbB2/ErbB3 Is Not Always Enough
Hynes, N. E., & Dey, J. H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.004 · Cited by 39
Figitumumab (CP-751,871) for cancer therapy
Gualberto, A. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003689980 · Cited by 39
LoRusso, P. M., Markman, B., Tabernero, J. M., Shazer, R. L., Nguyen, L. T., Heath, E. I., Patnaik, A., & Papadopoulos, K. P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3502 · Cited by 39
Untch, M., Loibl, S., Bischoff, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-s3-1 · Cited by 38
Yardley, D. A., Burris, H. A., Hanson, S., et al. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.029 · Cited by 26
Does Lapatinib Work against HER2-negative Breast Cancers?
Mayer, I., & Arteaga, C. L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3223 · Cited by 16
Self-citation
Cited by
Metabolic regulation of cell growth and proliferation
Zhu, J., & Thompson, C. B. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0123-5 · Cited by 1,116
Mazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., Mansuet-Lupo, A., Urban, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6095 · Cited by 668
Cancer-associated fibroblasts: from basic science to anticancer therapy
Yang, D., Liu, J., Qian, H., & Zhuang, Q. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01013-0 · Cited by 572
D'Souza-Schorey, C., & Clancy, J. W. (2012) · Genes & Development · doi:10.1101/gad.192351.112 · Cited by 528
The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases
Lemmon, M. A., Schlessinger, J., & Ferguson, K. M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020768 · Cited by 475
Metadata
- Authors
- Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2011-11-29
- Volume
- 9
- Issue
- 1
- Pages
- 16-32
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2000269004
- Cited by
- 861
- References
- 143
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.